Patents by Inventor Rafi Ahmed
Rafi Ahmed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180155430Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.Type: ApplicationFiled: June 28, 2017Publication date: June 7, 2018Applicants: Emory University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
-
Patent number: 9965516Abstract: A method and apparatus for outer-joined and/or cross-joined table elimination for duplicate-insignificant queries is provided. A query block of a query specifies a join between a first table and a second table. The join is one of an outer join and a cross join. A first determination is made that the query block contains no references to the second table to be processed after the join. A second determination is made that the query block is duplicate-insignificant. In response to making the first determination and the second determination, the query block is transformed into a transformed query, where the second table is eliminated from a corresponding query block in the transformed query.Type: GrantFiled: May 21, 2014Date of Patent: May 8, 2018Assignee: Oracle International CorporationInventors: Rafi Ahmed, Gautam Kumar Parai
-
Publication number: 20180101573Abstract: Techniques herein optimize sort-merge join method for a band join. In an embodiment, for a query comprising a query block specifying a join between a first table and a second table, a band join condition is detected between the first table and the second table. Once the band join condition in detected, an execution plan is generated and executed. The execution of the execution plan includes: for a first row of at least a subset of first sorted rows, scanning second rows from a set of second sorted rows, joining each of said second rows with said first row, and ceasing to scan when encountering a row from the second sorted rows that falls outside a bound of said band join condition. Techniques also include parallelizing a workload by overlapping the distribution of rows to the same slave process and computing cost and cardinality estimation for enhanced band join.Type: ApplicationFiled: October 5, 2017Publication date: April 12, 2018Inventors: Lei Sheng, Rafi Ahmed, Andrew Witkowski, Sankar Subramanian
-
Publication number: 20180081946Abstract: Attributes and semantics of duplicate insignificance that are inherent or inferred in a database language statement are detected. Also, a join operation that is inherent or inferred in the database language statement is detected and examined for join semantics. The join semantics specifies or refers to a driving table to be subjected to a hash join operation that may populate one or more hash buckets. The optimizer and the execution layers may use cost estimation or heuristics to assign the left and right table roles to the tables involved in the join. The hash join operation removes left table duplicates during population of the hash buckets, resulting in full or partial duplicate elimination that occurs during the hash join operation.Type: ApplicationFiled: March 9, 2017Publication date: March 22, 2018Applicant: Oracle International CorporationInventors: Srikanth BONDALAPATI, Rafi AHMED, Sankar SUBRAMANIAN
-
Patent number: 9870390Abstract: Methods, stored instructions, and computer systems are described for selecting an OR-expansion state of a query. A query processor accesses a certain query and a control parameter. The certain query comprises disjunctive predicates, and the control parameter indicates a certain procedure of a plurality of alternative stored procedures for expanding queries comprising disjunctive predicates into semantically equivalent candidate queries comprising combinations of subqueries. Based at least in part on the control parameter, the query processor selects the certain procedure to expand the certain query into one or more certain semantically equivalent candidate queries, each comprising a different combination of two or more subqueries. The query processor causes cost-based evaluation of subject queries, including the certain query and the one or more certain semantically equivalent candidate queries.Type: GrantFiled: February 18, 2014Date of Patent: January 16, 2018Assignee: Oracle International CorporationInventors: Rafi Ahmed, Nirav Vyas, Mohamed Zait
-
Publication number: 20170146520Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Applicants: Emory University, Dana-Farber Cancer Institute, Inc.Inventors: Rafi Ahmed, Rama Amara, Vijayakumar Velu, Kehmia Titanji, Gordon Freeman
-
Patent number: 9598491Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.Type: GrantFiled: November 27, 2009Date of Patent: March 21, 2017Assignees: Emory University, Dana-Farber Cancer Institute, Inc.Inventors: Rafi Ahmed, Rama Amara, Vijayakumar Velu, Kehmia Titanji, Gordon Freeman
-
Publication number: 20160362492Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.Type: ApplicationFiled: August 30, 2016Publication date: December 15, 2016Applicants: Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, President and Fellows of Harvard CollegeInventors: Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
-
Patent number: 9469685Abstract: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza.Type: GrantFiled: January 10, 2012Date of Patent: October 18, 2016Assignees: Emory University, The University of ChicagoInventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
-
Patent number: 9458226Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.Type: GrantFiled: October 12, 2010Date of Patent: October 4, 2016Assignees: Emory University, The University of ChicagoInventors: Jens Wrammert, Rafi Ahmed, Patrick Wilson
-
Patent number: 9457080Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.Type: GrantFiled: December 30, 2013Date of Patent: October 4, 2016Assignees: Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
-
Publication number: 20160200800Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.Type: ApplicationFiled: March 29, 2016Publication date: July 14, 2016Inventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
-
Publication number: 20160137731Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.Type: ApplicationFiled: August 10, 2015Publication date: May 19, 2016Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITYInventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
-
Patent number: 9321829Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.Type: GrantFiled: October 18, 2012Date of Patent: April 26, 2016Assignee: Emory UniversityInventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
-
Publication number: 20150339349Abstract: A method and apparatus for outer-joined and/or cross-joined table elimination for duplicate-insignificant queries is provided. A query block of a query specifies a join between a first table and a second table. The join is one of an outer join and a cross join. A first determination is made that the query block contains no references to the second table to be processed after the join. A second determination is made that the query block is duplicate-insignificant. In response to making the first determination and the second determination, the query block is transformed into a transformed query, where the second table is eliminated from a corresponding query block in the transformed query.Type: ApplicationFiled: May 21, 2014Publication date: November 26, 2015Inventors: Rafi Ahmed, Gautam Kumar Parai
-
Publication number: 20150239972Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.Type: ApplicationFiled: March 6, 2015Publication date: August 27, 2015Applicants: Emory University, Dana-Farber Cancer Institute, Inc.Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Vijayakumar Velu, Kehmia Titanji
-
Publication number: 20150234888Abstract: Methods, stored instructions, and computer systems are described for selecting an OR-expansion state of a query. A query processor accesses a certain query and a control parameter. The certain query comprises disjunctive predicates, and the control parameter indicates a certain procedure of a plurality of alternative stored procedures for expanding queries comprising disjunctive predicates into semantically equivalent candidate queries comprising combinations of subqueries. Based at least in part on the control parameter, the query processor selects the certain procedure to expand the certain query into one or more certain semantically equivalent candidate queries, each comprising a different combination of two or more subqueries. The query processor causes cost-based evaluation of subject queries, including the certain query and the one or more certain semantically equivalent candidate queries.Type: ApplicationFiled: February 18, 2014Publication date: August 20, 2015Applicant: Oracle International CorporationInventors: Rafi Ahmed, Nirav Vyas, Mohamed Zait
-
Patent number: 9102727Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.Type: GrantFiled: March 13, 2013Date of Patent: August 11, 2015Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
-
Publication number: 20140379690Abstract: A method, apparatus, and stored instructions are provided for transforming an initial query by eliminating a subquery nested within the initial query. The initial query may include an outer query that references a first instance of a particular data object. The initial query may also include set operator(s). At least a particular set operator may include a particular subquery that references a different instance of the particular data object. A query processor may transform the initial query to a transformed query that excludes the particular set operator and the particular subquery. The transformed query may instead include an added predicate that is based at least in part on the particular subquery. The added predicate may reference the first instance of the particular data object without referencing the different instance of the particular data object. The transformed query may be used for query execution instead of the initial query.Type: ApplicationFiled: June 20, 2013Publication date: December 25, 2014Inventors: Rafi Ahmed, Mohamed Zait
-
Publication number: 20140348851Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.Type: ApplicationFiled: October 18, 2012Publication date: November 27, 2014Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITYInventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson